Mazdutide 5mg

Mazdutide 5mg is formulated for research teams investigating dual GLP-1 and glucagon receptor agonism in experimental models. It is suited for laboratories studying receptor interaction behavior, comparative receptor signaling cascade dynamics, and dual-receptor pathway integration mechanisms in controlled preclinical systems. Research institutions examining receptor-level signaling modulation and downstream molecular endpoint differentiation will find Mazdutide a well-characterized compound for mechanistic experimental application. All Novera Mazdutide is manufactured in USA GMP-certified facilities to pharmaceutical-grade standards.

Dual-Receptor Interaction Research

Mazdutide enables concurrent investigation of GLP-1 and glucagon receptor-mediated interaction dynamics within experimental receptor signaling models. Research protocols may examine receptor binding profiles, signaling cascade integration behavior, and downstream molecular marker differentiation under defined exposure conditions. This dual-receptor engagement supports advanced preclinical study designs focused on receptor-level mechanism characterization.

Comparative Receptor Pathway Characterization

In experimental models, Mazdutide supports comparative analysis of dual-receptor signaling pathway behavior relative to single-receptor reference compounds. Study designs may evaluate differences in intracellular signaling cascade activation, pathway convergence, and receptor interaction dynamics to support systematic receptor pharmacology investigations.

Premium Formulation Quality

Advanced synthesis yields approximately 99% purity with verified dual-receptor activity, providing research teams with a reliable, well-characterized compound for receptor interaction and signal transduction experimental studies.

Integrated Molecular Endpoint Assessment

Mazdutide supports experimental evaluation across multiple intracellular signaling endpoints associated with GLP-1 and glucagon receptor engagement. Preclinical models may assess receptor-linked molecular marker behavior and signaling cascade integration without reference to physiological, metabolic, or clinical outcomes.

Storage Conditions

Lyophilized Mazdutide should be stored at 2–8°C in a cool, dark environment prior to reconstitution. Protection from light is essential to preserve peptide integrity. This product does not require cold chain shipping under standard laboratory receiving conditions.

Reconstitution Protocol

Reconstitute with sterile or bacteriostatic water under strict aseptic technique in accordance with institutional laboratory safety protocols. Following reconstitution, the solution must be refrigerated immediately and used within the timeframe specified in accompanying documentation.

Stability

Under proper laboratory storage conditions, reconstituted Mazdutide maintains stability in accordance with institutional handling standards. Lyophilized material stored at recommended temperatures retains integrity for extended periods. All handling should adhere to institutional biosafety and laboratory best practices.

Experimental Study Duration

Preclinical protocols examining receptor interaction dynamics and downstream signaling pathway markers may span variable durations depending on experimental objectives. Sampling cadence, endpoint selection, and observation windows should be defined by the study design and institutional laboratory standards.

USA GMP Manufacturing

Novera produces Mazdutide in certified USA GMP facilities under rigorous quality controls. Each vial is accompanied by a comprehensive Certificate of Analysis (COA) confirming dual-agonist peptide purity and integrity. The compound is intended exclusively for analytical and laboratory research purposes.

• CAS: 2259884-03-0
• Chemical Formula: C₂₁₀H₃₂₂N₄₆O₆₇
• Molecular Weight: 4563.06 g/mol
• Peptide Sequence: His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-Nonadecanoic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
• Synonyms: IBI-362 (or IBI362) LY-3305677 (or LY3305677)
• Shelf life: 24 months from the manufacturing date.

Balanced Dual GLP-1/Glucagon Receptor Agonism

Mazdutide engages both GLP-1 and glucagon receptors in calibrated ratios, enabling simultaneous investigation of complementary receptor interaction dynamics and downstream intracellular signaling pathway marker behavior in experimental models. GLP-1 receptor engagement and glucagon receptor engagement can be examined individually or in combination to characterize receptor-specific and integrated signaling cascade patterns. This dual-receptor configuration supports comparative mechanistic studies relative to single-receptor reference ligands in preclinical research settings.

Dual-Receptor Signaling Pathway Investigation

Mazdutide supports experimental investigation of downstream signaling pathway activation following dual GLP-1 and glucagon receptor engagement. Research applications include characterization of receptor-specific signal transduction pathways, second messenger cascade dynamics, and pathway integration behavior under controlled laboratory conditions. The compound enables systematic study of receptor co-activation effects at the molecular signaling level without reference to physiological outcomes.

USA GMP Manufacturing

Novera produces Mazdutide in certified USA GMP facilities under rigorous quality controls. Each vial is accompanied by a comprehensive Certificate of Analysis (COA) confirming dual-agonist peptide purity and integrity. The compound is intended exclusively for analytical and laboratory research purposes.

Mazdutide (IBI362) is an acylated peptide dual agonist that co-activates GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR). It belongs to the GLP-1R/GCGR co-agonist class and is studied in research models as a tool compound for investigating the combined effects of incretin and glucagon pathway co-activation on metabolic signalling, hepatic lipid metabolism, and energy homeostasis.

In research models, adding glucagon receptor activity to GLP-1R agonism introduces hepatic effects including FGF21 induction, increased fatty acid oxidation, and mitochondrial biogenesis that are not observed with GLP-1R agonism alone. The challenge of the dual agonist design — and an active area of research with Mazdutide — is characterising how GCGR-driven gluconeogenesis is offset by GLP-1R-driven insulin secretion at different receptor activity ratios.

GLP-1R pharmacology is characterised in GLP-1R-expressing HEK293 or CHO cells using cAMP accumulation assays, with semaglutide or native GLP-1(7-36)amide as reference agonists. GCGR pharmacology is characterised in GCGR-expressing systems using the same cAMP readout, with native glucagon as the reference. Primary hepatocyte cultures provide a more physiologically relevant model for characterising Mazdutide’s combined receptor effects on glucose and lipid metabolism endpoints.

Lyophilised Mazdutide should be stored at -20°C in dry, dark conditions. Reconstitution should be performed in sterile aqueous buffer (PBS or sterile water), and solutions should be aliquoted and stored at -80°C to minimise activity loss from freeze-thaw cycling. Mass spectrometric confirmation of molecular identity and acylation should be documented per batch.

Mazdutide as supplied by Elivena is for research use in controlled laboratory settings only. While Mazdutide is in clinical development, the research compound supplied here is not approved for human therapeutic administration outside formally registered clinical trial programmes.